Insulet Corp (PODD) 43.66 $PODD
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 1.25 (-0.07), JNJ: 104.43 (-2.29), PODD: 43.66 (-1.56), MDT: 72.52 (-1.25)
Insulet Up 23.2% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Mon Dec 08, 9:49AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 3 months, Insulet has returned 23.16% as of today's recent price of $46.59.
PODD: 43.66 (-1.56)
DexCom CEO Terry Gregg Explains 50% YTD Stock Leap, Plans for 2015
at The Street - Wed Dec 03, 3:54PM CST
DexCom shares are up over 50% for the year on four FDA approvals. CEO Terry Gregg says technology is driving its products to the forefront.
JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), PODD: 43.66 (-1.56), DXCM: 53.66 (-0.67), TNDM: 11.56 (-0.27), AAPL: 109.73 (-1.89)
Next-Generation OmniPod Pumping Up Profitability At Insulet Corp.
Cory Renauer - Seeking Alpha - Wed Dec 03, 1:26PM CST
I'm beginning coverage of Insulet Corporation (NASDAQ: PODD ) with a somewhat buy recommendation. The long case is largely based on rapid revenue growth, expanding margins, and a potential takeover. When recently appointed CEO Patrick Sullivan took...
PODD: 43.66 (-1.56)
Insulet Has Returned 19.7% Since SmarTrend Recommendation (PODD)
Comtex SmarTrend(R) - Mon Dec 01, 9:23AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 19.67% as of today's recent price of $45.27.
PODD: 43.66 (-1.56)
Insulet Corporation to Present at Upcoming Investor Conferences
Marketwired - Mon Nov 24, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to participate in the following upcoming investor conferences:
PODD: 43.66 (-1.56)
Insulet Earnings Review: 19 Days after Announcement Shares Up 12.4% (PODD)
Comtex SmarTrend(R) - Mon Nov 24, 8:45AM CST
Two weeks ago on November 5th, 2014 Insulet (NASDAQ ODD) reported earnings and analysts, on average, expected a loss of $0.01 on sales of $75.3 million. Insulet actually reported a loss of $0.19 per share on sales of $75.0 million, missing EPS estimates by $0.18 and matching revenue estimates. Shares of Insulet have climbed from $40.27 to $45.26, representing a gain of 12.4% since the company reported earnings 19 days ago.
PODD: 43.66 (-1.56)
Insulet Up 19.6% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Fri Nov 21, 4:52PM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 19.64% as of today's recent price of $45.26.
PODD: 43.66 (-1.56)
Post Earnings Update: Insulet Has Climbed 12.2% Higher in Past Week (PODD)
Comtex SmarTrend(R) - Mon Nov 17, 2:58PM CST
12 days ago, on November 5th, 2014, Insulet (NASDAQ ODD) reported its earnings. Analysts, on average, expected a loss of $0.01 per share on sales of $75.3 million. The company actually reported a loss of $0.19 per share on sales of $75.0 million, missing EPS estimates by $0.18 and matching revenue estimates. Since the company's report, shares of Insulet have risen from $40.27 to $45.17, representing a gain of 12.2% in the past 12 days.
PODD: 43.66 (-1.56)
Uptrend Call Working As Insulet Stock Rises 20.9% (PODD)
Comtex SmarTrend(R) - Fri Nov 14, 11:12AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 20.86% as of today's recent price of $45.72.
PODD: 43.66 (-1.56)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), PODD: 43.66 (-1.56), NVO: 44.48 (-1.14), MDT: 72.52 (-1.25), LLY: 69.55 (-2.06)
Insulet's (PODD) CEO Patrick Sullivan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:41PM CST
PODD: 43.66 (-1.56)
Insulet tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 4:27PM CST
BEDFORD, Mass. (AP) _ Insulet Corp. (PODD) on Wednesday reported a loss of $10.8 million in its third quarter.
PODD: 43.66 (-1.56)
Insulet misses by $0.18, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:13PM CST
PODD: 43.66 (-1.56)
Insulet (PODD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
PODD: 43.66 (-1.56)
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human Resources
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the promotion of Allison Dorval to Chief Financial Officer effective November 6, 2014 and Brad Thomas as Executive Vice President, Human Resources and Organizational Development, effective immediately.
PODD: 43.66 (-1.56)
Insulet Reports Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the three and nine months ended September 30, 2014.
PODD: 43.66 (-1.56)
Insulet Shares Up 14.4% Since SmarTrend's Buy Recommendation (PODD)
Comtex SmarTrend(R) - Fri Oct 31, 9:34AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 14.43% as of today's recent price of $43.29.
PODD: 43.66 (-1.56)
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 1.25 (-0.07), JNJ: 104.43 (-2.29), PODD: 43.66 (-1.56), MDT: 72.52 (-1.25)
Insulet Up 23.2% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Mon Dec 08, 9:49AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 3 months, Insulet has returned 23.16% as of today's recent price of $46.59. PODD: 43.66 (-1.56)
DexCom CEO Terry Gregg Explains 50% YTD Stock Leap, Plans for 2015
at The Street - Wed Dec 03, 3:54PM CST
DexCom shares are up over 50% for the year on four FDA approvals. CEO Terry Gregg says technology is driving its products to the forefront.
JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), PODD: 43.66 (-1.56), DXCM: 53.66 (-0.67), TNDM: 11.56 (-0.27), AAPL: 109.73 (-1.89)
Next-Generation OmniPod Pumping Up Profitability At Insulet Corp.
Cory Renauer - Seeking Alpha - Wed Dec 03, 1:26PM CST
I'm beginning coverage of Insulet Corporation (NASDAQ: PODD ) with a somewhat buy recommendation. The long case is largely based on rapid revenue growth, expanding margins, and a potential takeover. When recently appointed CEO Patrick Sullivan took...
PODD: 43.66 (-1.56)
Insulet Has Returned 19.7% Since SmarTrend Recommendation (PODD)
Comtex SmarTrend(R) - Mon Dec 01, 9:23AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 19.67% as of today's recent price of $45.27. PODD: 43.66 (-1.56)
Insulet Corporation to Present at Upcoming Investor Conferences
Marketwired - Mon Nov 24, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to participate in the following upcoming investor conferences:
PODD: 43.66 (-1.56)
Insulet Earnings Review: 19 Days after Announcement Shares Up 12.4% (PODD)
Comtex SmarTrend(R) - Mon Nov 24, 8:45AM CST
Two weeks ago on November 5th, 2014 Insulet (NASDAQ
ODD) reported earnings and analysts, on average, expected a loss of $0.01 on sales of $75.3 million. Insulet actually reported a loss of $0.19 per share on sales of $75.0 million, missing EPS estimates by $0.18 and matching revenue estimates. Shares of Insulet have climbed from $40.27 to $45.26, representing a gain of 12.4% since the company reported earnings 19 days ago. PODD: 43.66 (-1.56)
Insulet Up 19.6% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Fri Nov 21, 4:52PM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 19.64% as of today's recent price of $45.26. PODD: 43.66 (-1.56)
Post Earnings Update: Insulet Has Climbed 12.2% Higher in Past Week (PODD)
Comtex SmarTrend(R) - Mon Nov 17, 2:58PM CST
12 days ago, on November 5th, 2014, Insulet (NASDAQ
ODD) reported its earnings. Analysts, on average, expected a loss of $0.01 per share on sales of $75.3 million. The company actually reported a loss of $0.19 per share on sales of $75.0 million, missing EPS estimates by $0.18 and matching revenue estimates. Since the company's report, shares of Insulet have risen from $40.27 to $45.17, representing a gain of 12.2% in the past 12 days. PODD: 43.66 (-1.56)
Uptrend Call Working As Insulet Stock Rises 20.9% (PODD)
Comtex SmarTrend(R) - Fri Nov 14, 11:12AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 2 months, Insulet has returned 20.86% as of today's recent price of $45.72. PODD: 43.66 (-1.56)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), PODD: 43.66 (-1.56), NVO: 44.48 (-1.14), MDT: 72.52 (-1.25), LLY: 69.55 (-2.06)
Insulet's (PODD) CEO Patrick Sullivan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:41PM CST
PODD: 43.66 (-1.56)
Insulet tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 4:27PM CST
BEDFORD, Mass. (AP) _ Insulet Corp. (PODD) on Wednesday reported a loss of $10.8 million in its third quarter.
PODD: 43.66 (-1.56)
Insulet misses by $0.18, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:13PM CST
PODD: 43.66 (-1.56)
Insulet (PODD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
PODD: 43.66 (-1.56)
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human Resources
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the promotion of Allison Dorval to Chief Financial Officer effective November 6, 2014 and Brad Thomas as Executive Vice President, Human Resources and Organizational Development, effective immediately.
PODD: 43.66 (-1.56)
Insulet Reports Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the three and nine months ended September 30, 2014.
PODD: 43.66 (-1.56)
Insulet Shares Up 14.4% Since SmarTrend's Buy Recommendation (PODD)
Comtex SmarTrend(R) - Fri Oct 31, 9:34AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 14.43% as of today's recent price of $43.29. PODD: 43.66 (-1.56)
